Personalized treatment is better than one treatment fits all in the management of patients with mCRC: A consensus statement

Future Oncology

Volumn 10, Issue 16, 2014, Pages 2643-2657

  Yalcin, Suayib ^a   Trad, Diaeddine ^b   Kader, Yasser Abdel ^c   Halawani, Hafez ^d   Demir, Osman Gokhan ^e   Mall, Riaz ^f   Meshcheryakov, Andrey ^g   Nasr, Fadi ^h   Nosworthy, Adam ⁱ   Osinsky, Dmitry ^j   Tumanova, Assel ^k   Turhal, Serdar ^l   Tejpar, Sabine ^m   Köhne, Claus Henning ⁿ  

^a HACETTEPE UNIVERSITY   (Turkey)

^b TAWAM HOSPITAL   (United Arab Emirates)

^c Kasr Alainy Hospital   (Egypt)

^d KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

^e FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

^f Hopelands Cancer Centre   (South Africa)

^g N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^h MOUNT LEBANON HOSPITAL   (Lebanon)

ⁱ University of the Witwatersrand   (South Africa)

^j Kiev City Oncology Centre   (Ukraine)

^k Kazakh Veterinary Research Institute   (Kazakhstan)

^l MARMARA UNIVERSITY   (Turkey)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ KLINIKUM OLDENBURG   (Germany)

more..

Author keywords

bevacizumab; cetuximab; consensus treatment recommendations; first line; metastatic colorectal cancer; panitumumab; RAS mutation status

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; PANITUMUMAB; VASCULOTROPIN;

AFRICA; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CENTRAL ASIAN; CONSENSUS; HUMAN; LIVER RESECTION; METASTATIC COLORECTAL CANCER; MIDDLE EAST; ONCOGENE; ONCOGENE RAS; ONCOLOGIST; PERSONALIZED MEDICINE; REVIEW; RUSSIAN FEDERATION; SURVIVAL RATE; TURKEY (REPUBLIC);

EID: 84919832058     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.203     Document Type: Review

References (86)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46(4), 765-781 (2010).
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010).
3. Kohne CH, Cunningham D, Di Costanzo F et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann. Oncol. 13(2), 308-317 (2002).
4. Sanoff HK, Mcleod HL. Predictive factors for response and toxicity in Chemotherapy: Pharmacogenomics. Semin. Colon Rectal Surg. 19(4), 226-230 (2008).
5. Diaz R, Aparicio J, Girones R et al. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based Chemotherapy. Clin. Colorectal Cancer 5(3), 197-202 (2005).
6. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann. Oncol. 23(10), 2479-2516 (2012).
7. Van Cutsem E, Dicato M, Arber N et al. Molecular markers and biological targeted therapies in metastatic colorectal cancer: Expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann. Oncol. 21(Suppl. 6), vi1-vi10 (2010).
8. Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann. Oncol. 21(Suppl. 5), v93-v97 (2010).
9. Cartwright TH. Treatment decisions after diagnosis of metastatic colorectal cancer. Clin. Colorectal Cancer 11(3), 155-166 (2012).
10. Adam R, De Gramont A, Figueras J et al. The oncosurgery approach to managing liver metastases from colorectal cancer: A multidisciplinary international consensus. Oncologist 17(10), 1225-1239 (2012).
11. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and Chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
12. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011-2019 (2011).
13. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663-671 (2009).
14. Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann. Oncol. 22(7), 1535-1546 (2011).
15. Douillard JY, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J. Clin. Oncol. 28(31), 4697-4705 (2010).
16. Bokemeyer C, Van Cutsem E, Rougier P et al. Addition of cetuximab to Chemotherapy as first-line treatment for KRAS wild-Type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer 48(10), 1466-1475 (2012).
17. Bokemeyer C, Kohne C, Ciardiello F et al. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. J. Clin. Oncol. 32(5s Suppl.), Abstract 3505 (2014).
18. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369(11), 1023-1034 (2013).
19. Douillard JY, Siena S, Cassidy J et al. Final results from PRIME: Randomized Phase 3 study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann. Oncol. 25(7), 1346-1355 (2014).
20. Oliner KS, Douillard J-Y, Siena S et al. Analysis of KRAS/NRAS and BRAF mutations in the Phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). J. Clin. Oncol. 31(Suppl.), Abstract 3511 (2013).
21. Ciardiello F, Lenz HJ, Kohne C et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J. Clin. Oncol. 32(5s, Suppl.), Abstract 3506 (2014).
22. Piessevaux H, Buyse M, Schlichting M et al. Use of early tumor shrinkage to predict long-Term outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 31(30), 3764-3775 (2013).
23. Mansmann UR, Laubender RP, Sartorius U, Giessen CA, Graser A, Heinemann V. Improved early prediction of individual prognosis for patients with mCRC: Joint modeling of tumor shrinkage with volume data for PFS and OS. J. Clin. Oncol. 30(Suppl. 15), Abstract 3603 (2012).
24. Mansmann UR, Sartorius U, Laubender RP, Giessen CA, Esser R, Heinemann V. Deepness of response: A quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC. J. Clin. Oncol. 30(Suppl. 4), Abstract 427 (2012).
25. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination Chemotherapy for treatment of advanced colorectal cancer: Results of the randomised Phase 3 MRC COIN trial. Lancet 377(9783), 2103-2114 (2011).
26. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: Analysis of a Phase III study of bevacizumab with Chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14(1), 22-28 (2009).
27. Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/ folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol. 26(12), 2006-2012 (2008).
28. Heinemann V, Fischer Von Weikersthal L, Decker T et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-Type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J. Clin. Oncol. 31(Suppl. 15), Abstract LBA3506 (2013).
29. Schwartzberg LS, Rivera F, Karthaus M et al. PEAK: A randomized, multicenter Phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-Type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol, 32(21), 2240-2247 (2014).
30. Venook A, Niedzwiecki D, Lenz HJ et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-Type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J. Clin. Oncol. 32(5s, Suppl.), Abstract LBA3 (2014).
31. Van Cutsem E, Nordlinger B, Adam R et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur. J. Cancer 42(14), 2212-2221 (2006).
32. Nordlinger B, Van Cutsem E, Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: Recommendations from an expert panel. Ann. Oncol. 20(6), 985-992 (2009).
33. Nordlinger B, Van Cutsem E, Rougier P et al. Does Chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur. J. Cancer 43(14), 2037-2045 (2007).
34. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann. Oncol. 16(8), 1311-1319 (2005).
35. Van Cutsem E, Bokemeyer C, Heeger S, Sartorius U, Rougier P, Kohne C. Outcome according to metastatic site in patients with KRAS wild-Type tumors: Analysis from the CRYSTAL and OPUS studies. J. Clin. Oncol. 29(Suppl. 4), Abstract 472 (2011).
36. Kohne C, Bokemeyer C, Heeger S, Sartorius U, Rougier P, Van Cutsem E. Efficacy of Chemotherapy plus cetuximab according to metastatic site in KRAS wild-Type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL and OPUS studies. J. Clin. Oncol. 29(Suppl. 15), Abstract 3576 (2011).
37. Ye LC, Liu TS, Ren L et al. Randomized controlled trial of cetuximab plus Chemotherapy for patients with KRAS wild-Type unresectable colorectal liver-limited metastases. J. Clin. Oncol. 31(16), 1931-1938 (2013).
38. Primrose J, Falk S, Finch-Jones M et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. Lancet Oncol. 15(6), 601-611 (2014).
39. Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study. J. Clin. Oncol. 30(15), 1755-1762 (2012).
40. Ku GY, Haaland BA, De Lima Lopes Jr. G. Cetuximab in the first-line treatment of K-ras wild-Type metastatic colorectal cancer: The choice and schedule of fluoropyrimidine matters. Cancer Chemother. Pharmacol. 70(2), 231-238 (2012).
41. Arkenau HT, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: A pooled analysis of randomized trials. J. Clin. Oncol. 26(36), 5910-5917 (2008).
42. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based Chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized Phase III study. J. Clin. Oncol. 26(12), 2013-2019 (2008).
43. Wong NS, Fernando NH, Nixon AB et al. A Phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res. 31(1), 255-261 (2011).
44. Gruenberger T, Bridgewater J, Chau I et al. Randomized, Phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA. J. Clin. Oncol. 31(Suppl. 15), Abstract 3619 (2013).
45. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
46. Folprecht G, Gruenberger T, Bechstein W et al. Cetuximab and Chemotherapy in the treatment of patients with initially 'nonresectable' colorectal (CRC) liver metastases: Long-Term follow-up of the CELIM trial. J. Clin. Oncol. 31(Suppl. 15), Abstract 3538 (2013).
47. Suzuki C, Blomqvist L, Sundin A et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination Chemotherapy. Ann. Oncol. 23(4), 948-954 (2012).
48. Mansmann UR, Laubender RP, Giessen CA, Sartorius U, Heinemann V. Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC). J. Clin. Oncol. 30(Suppl. 4), Abstract 580 (2012).
49. Piessevaux H, Buyse M, De Roock W et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann. Oncol. 20(8), 1375-1382 (2009).
50. Piessevaux H, Van Cutsem E, Bokemeyer C, Schlichting M, Heeger S, Tejpar S. Early tumor shrinkage and long-Term outcome in metastatic colorectal cancer (mCRC): Assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies. J. Clin. Oncol. 29(Suppl. 15), Abstract 3572 (2011).
51. Falcone A, Cremolini C, Masi G et al. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the Phase III TRIBE trial by GONO group. J. Clin. Oncol. 31(Suppl. 15), Abstract 3505 (2013).
52. Mansmann UR, Sartorius U, Laubender RP, Giessen CA, Esser R, Heinemann V. Deepness of Response: A quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC. J. Clin. Oncol. 30(Suppl. 4), Abstract 427 (2013).
53. Mansmann UR, Sartorius U, Laubender RP, Giessen CA, Esser R, Heinemann V. Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC. J. Clin. Oncol. 31(Suppl.), Abstract 3630 (2013).
54. Mansmann UR, Sartorius U, Laubender RP, Giessen CA, Esser R, Heinemann V. Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC. Ann. Oncol (Suppl.), Abstract O-0009 (2013).
55. Stintzing S, Jung A, Rossius L et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized Phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-Type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. European Cancer Congress 2013, Brussels, Belgium, Abstract 17 (2013).
56. Heinemann V, Modest DP, Fischer Von Weikersthal L et al. Independent radiological evaluation of objective response early tumor shrinkage and depth of response in FIRE-3 (AIO KRK-0306). Ann. Oncol. 25(Suppl. 2), Abstract O-0030 (2014).
57. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25(13), 1670-1676 (2007).
58. Loupakis F, Cremolini C, Salvatore L et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur. J. Cancer 50(1), 57-63 (2014).
59. Goldberg RM, Kohne CH, Seymour MT et al. A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (mCRC). J. Clin. Oncol. 25(18S), Abstract 4011 (2007).
60. Lang I, Kohne CH, Folprecht G et al. Quality of life analysis in patients with KRAS wild-Type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. Eur. J. Cancer 49(2), 439-448 (2013).
61. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. 23(16), 3706-3712 (2005).
62. Tebbutt NC, Wilson K, Gebski VJ et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian gastrointestinal trials group randomized Phase III MAX study. J. Clin. Oncol. 28(19), 3191-3198 (2010).
63. Stathopoulos GP, Batziou C, Trafalis D et al. Treatment of colorectal cancer with and without bevacizumab: A Phase III study. Oncology 78(5-6), 376-381 (2010).
64. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann. Oncol. 20(11), 1842-1847 (2009).
65. Sobrero A, Ackland S, Clarke S et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77(2), 113-119 (2009).
66. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J. Clin. Oncol. 26(4), 689-690 (2008).
67. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J. Clin. Oncol. 25(30), 4779-4786 (2007).
68. Saltz L, Clarke S, Diaz-Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized Phase III trial in first-line metastatic colorectal cancer. J. Clin. Oncol. 25(Suppl. 18), Abstract 4028 (2007).
69. Yalcin S, Uslu R, Dane F et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: Phase III 'Stop and Go' study results-A Turkish Oncology Group Trial. Oncology 85(6), 328-335 (2013).
70. Koopman M, Simkens L, May AM, Mol L, Van Tinteren H, Punt CJA. Final results and subgroup analyses of the Phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with Chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC). J. Clin. Oncol. 32(Suppl. 5), Abstract 3504 (2014).
71. Cunningham D, Lang I, Marcuello E et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised Phase 3 trial. Lancet Oncol. 14(11), 1077-1085 (2013).
72. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised Phase 3 trial. Lancet Oncol. 14(1), 29-37 (2013).
73. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499-3506 (2012).
74. Tabernero J, Van Cutsem E, Lakomy R et al. Results from VELOUR, a Phase 3 study of aflibercept (A) versus placebo (pbo) in combination with FOLFIRI for the treatment of patients (pt) with previously treated metastatic colorectal cancer (MCRC). Eur. J. Cancer 47(Suppl. 2), 5 (2011).
75. Masi G, Loupakis F, Salvatore L et al. Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the Phase III 'BEBYP' trial by the Gruppo Oncologico Nord Ovest (GONO). J. Clin. Oncol. 31(Suppl. 15), Abstract 3615 (2013).
76. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007).
77. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
78. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357(20), 2040-2048 (2007).
79. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
80. Peeters M, Price TJ, Cervantes A et al. Randomized Phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(31), 4706-4713 (2010).
81. Allegra CJ, Lakomy R, Tabernero J et al. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A Phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. J. Clin. Oncol. 30(Suppl. 15), Abstract 3505 (2012).
82. Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, Prenen H. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther. 6, 53-58 (2013).
83. Davis SL, Eckhardt SG, Messersmith WA, Jimeno A. The development of regorafenib and its current and potential future role in cancer therapy. Drugs Today (Barc) 49(2), 105-115 (2013).
84. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 303-312 (2013).
85. Benson AB 3rd, Bekaii-Saab T, Chan E et al. Metastatic colon cancer, version 3.2013: Featured updates to the NCCN Guidelines. J. Natl Compr. Canc. Netw. 11(2), 141-152 (2013).
86. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J. Clin. Oncol. 22(2), 229-237 (2004).